Human Papillomavirus Infection Clinical Trial
Official title:
Implementation of Evidence-Based Strategies to Optimize HPV Vaccination in Rural Primary Care Settings
This study evaluates the implementation of evidence based strategies to optimize HPV vaccination in rural primary care settings. Some of the largest disparities in human papillomavirus vaccination (HPVV) rates exist in rural communities, which represent missed opportunities for cancer prevention. Primary care provider visits in these communities serve as a crucial opportunity to communicate the importance of timely vaccination that is essential to effective cancer prevention. This study implements and tests a practice-level intervention (PC TEACH) using practice facilitation of evidence-based strategies to expand reach to rural community-based primary care settings to optimize delivery and increase HPVV rates. PC TEACH program may help rural communities overcome access and awareness factors that keep them from receiving HPVV.
PRIMARY OBJECTIVES: I. Identify practices from across 20 rural counties in central and western New York (CWNY) using registry data from New York State Immunization Information System. II. Leverage established community network contacts of primary care practices across 20 rural counties in CWNY to support and enhance recruitment and retention activities. III. Establish a Rural Cancer Health Equity Community Advisory Board (CAB) to enhance capacity to implement evidence-based cancer prevention activities in rural primary care settings (like primary care practice-level, medical office-based intervention [PC-TEACH] for Human Papilloma Virus Vaccine [HPVV]). IV. Recruit rural primary care practices to implement PC TEACH intervention and contribute practice, provider, and patient-level data including adolescent vaccination rates. V. Implement systematic practice-level changes (i.e., PC TEACH strategies) in rural community-based primary care practices. V. Evaluate effectiveness of PC TEACH intervention and quality improvement within the practices using process and outcome evaluation measures. OUTLINE: Primary practice providers sites receive PC TEACH over 3.5 hours for 12 months. After completion of study, primary care provider sites are followed up for 3-6 months. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05458869 -
Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
|
||
Completed |
NCT01932697 -
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
|
Phase 2 | |
Completed |
NCT03265743 -
HPV Vaccination in Women With Cystic Fibrosis
|
N/A | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A | |
Completed |
NCT06199128 -
Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients
|
||
Active, not recruiting |
NCT01824537 -
Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
|
Phase 4 | |
Terminated |
NCT01082861 -
Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination
|
Phase 4 | |
Unknown status |
NCT01087164 -
Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers
|
N/A | |
Completed |
NCT01265212 -
Prevalence of Human Papillomavirus in Men Living in the Northern Plains
|
N/A | |
Completed |
NCT00572832 -
Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting
|
N/A | |
Completed |
NCT03158220 -
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
|
Phase 3 | |
Recruiting |
NCT05210348 -
Clinical Evaluation of Detection of High Risk HPV in Urine
|
||
Completed |
NCT05680454 -
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
|
Phase 1 | |
Completed |
NCT04133610 -
HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs
|
N/A | |
Completed |
NCT00988884 -
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)
|
Phase 3 | |
Not yet recruiting |
NCT05981807 -
HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
|
||
Recruiting |
NCT03302858 -
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand
|
Phase 2 | |
Completed |
NCT01694875 -
Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System
|
N/A | |
Completed |
NCT01158209 -
An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus Types in Women in Egypt
|
N/A |